In the News The future of oncology therapies: Stingray Therapeutics’ immune-boosting breakthrough 4 Houston life science startups secure over $40M in CPRIT funding Development of a potent and selective oral ENPP1 inhibitor for oncology $2 MILLION SBIR DIRECT TO PHASE II AWARD FUNDS THERAPEUTIC DEVELOPMENT AND TESTING AT STINGRAY THERAPEUTICS AND TGEN Founder Stories: Jon Northrup, Stingray Therapeutics How Stingray Therapeutics Raised $2.5M | Newchip Reviews Founder Stories: TGEN APPOINTS DR. SUNIL SHARMA PHYSICIAN-IN-CHIEF
